BioTech
GSK

GSK-J&J's long-acting HIV injection gets EU panel endorsement

Credit: REUTERS/MATTHEW CHILDS

GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

Adds details on panel recommendation, share movement, background

Oct 16 (Reuters) - GlaxoSmithKline Plc GSK.L said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's JNJ.N rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

The treatment is a long-acting regimen, which can reduce the number of doses required to 12 or six per year instead of a daily intake of pills.

If approved, it would be the first complete long-acting HIV regimen requiring dosing just once in two months (in the EU region), GSK said. The combination as an injection is already approved in Canada and is currently under review in the United States.

Shares of GSK were trading up 2.5% at 1410.4p, while J&J shares were marginally up during premarket trading.

Gilead's GILD.O Truvada daily oral pill is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit.

The positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency comes months after GSK said cabotegravir was found to be 66% more effective in preventing HIV infections than Truvada.

Some 75 million people worldwide have been infected with HIV and about 32 million people have died since it began in the 1980s.

While final approvals are up to the European Commission, it generally follows the CHMP's recommendation and endorses them within a couple of months.

(Reporting by Aakash Jagadeesh Babu and Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)

((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK JNJ GILD

Other Topics

US Markets

Latest BioTech Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More